Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).

Belfiglio, Maurizio; Valentini, Miriam; Pellegrini, Fabio; De Berardis, Giorgia; Franciosi, Monica; Rossi, Maria C E; Sacco, Michele; Nicolucci, Antonio

Belfiglio, Maurizio; Valentini, Miriam; Pellegrini, Fabio; De Berardis, Giorgia; Franciosi, Monica; Rossi, Maria C E; Sacco, Michele; Nicolucci, Antonio.

Affiliation

Belfiglio M; Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.

Cancer ; 104(11): 2334-9, 2005 Dec 01.

Article in En | MEDLINE | ID: mdl-16245354

Subject(s)

Breast Neoplasms/drug therapy; Postmenopause; Tamoxifen/therapeutic use; Age Factors; Aged; Antineoplastic Agents, Hormonal/therapeutic use; Breast Neoplasms/mortality; Breast Neoplasms/pathology; Chemotherapy, Adjuvant; Female; Humans; Italy; Middle Aged; Neoplasm Staging; Receptors, Estrogen/analysis; Survival Analysis

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tamoxifen / Breast Neoplasms / Postmenopause Type of study: Clinical_trials Limits: Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Cancer Year: 2005 Document type: Article Affiliation country: Italy Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links